Dog Vaccines Market Report 2025

The dog vaccines market size has grown strongly in recent years. It will grow from $3.61 billion in 2024 to $3.81 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to innovative vaccination protocols, zoonotic disease awareness, globalization and travel, educational campaigns, research and vaccine development, veterinary practice evolution.

The dog vaccines market size is expected to see strong growth in the next few years. It will grow to $5.08 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing pet adoption rates, health consciousness among pet owners, government regulations and mandates, rising humanization of pets, prevalence of canine diseases. Major trends in the forecast period include pet insurance and healthcare plans, availability and accessibility, customized vaccination protocols, changing disease patterns, development of novel vaccines.

The increasing adoption of pet dogs is anticipated to drive the growth of the dog vaccines market in the future. A pet dog is defined as a domesticated or tamed companion animal that lives in a household. Dog vaccines are injections administered in a series, beginning in the puppy stage and continuing into adulthood. These vaccines stimulate the immune system, helping dogs to confront microorganisms and either avoid illness or experience less severe symptoms. For example, according to the National Pet Owners Survey conducted by the American Pet Products Association for 2021-2022, a US-based non-profit industry association, 70% of households in the United States owned a pet, equating to 90.5 million homes. Among these, 69 million U.S. households had a dog as a pet, the highest number compared to other types of pets. Therefore, the rise in the adoption of pet dogs is contributing to the growth of the dog vaccines market.

The increasing prevalence of zoonotic diseases is projected to drive the growth of the dog vaccines market in the future. Zoonotic diseases, also referred to as zoonoses, are infectious diseases that can be transmitted naturally between animals and humans and vice versa. Dog vaccines are essential in preventing the transmission of zoonotic diseases from dogs to humans and play a significant role in public health initiatives aimed at controlling and managing zoonotic infections. For example, in February 2023, the Council on Foreign Relations (CFR), a US-based independent, nonpartisan think tank and publisher, reported that up to 75% of newly discovered or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases have zoonotic origins. Globally, zoonoses result in 2.7 million human deaths and 2.5 billion instances of disease annually. Thus, the increasing prevalence of zoonotic diseases is fueling the growth of the dog vaccines market.

Technological advancements are emerging as a prominent trend in the dog vaccines market. Leading companies in the market are leveraging novel technologies for vaccine development. Merck Animal Health, a notable player, introduced Nobivac Intra-Trac Oral BbPi in September 2022. This oral vaccine, featuring mucosal protection and easy administration, represents a technological leap forward. It employs the innovative Immuno-Mist-R technology by Intervet, a Merck & Co subsidiary, significantly enhancing mucosal surface area contact. This technological progress in vaccine development contributes to the effectiveness and ease of administration in the dog vaccines market.

Major companies in the dog vaccines market are concentrating on innovative rabies vaccines to gain a competitive edge. The introduction of a three-dose rabies vaccine by Cadila Pharmaceuticals exemplifies this focus on innovation. Launched in April 2022, ThRabis is a recombinant nanoparticle-based rabies G protein vaccine, utilizing virus-like particle technology. The vaccine, generated from cloned genes expressed in insect cells, neutralizes the rabies virus and prevents its attachment to cells. This innovation in rabies vaccines addresses key aspects of effectiveness, accessibility, and administration, positioning companies at the forefront of the competitive landscape in the dog vaccines market.

In September 2024, Boehringer Ingelheim, a Germany-based company active in both the human and animal health sectors, acquired Saiba Animal Health AG for an undisclosed sum. This acquisition bolsters Boehringer Ingelheim's research and development capabilities in the animal health sector, with a particular emphasis on innovative therapeutic vaccines for pets that target chronic diseases like allergies, inflammation, and pain. Saiba Animal Health AG is a Switzerland-based company that specializes in providing dog vaccines.

Major companies operating in the dog vaccines market are Vetoquinol S.A., Boehringer Ingelheim GmbH, Ceva Sante Animale, Heska Corporation, Merck & Co. Inc., Virbac Animal Health Pvt. Ltd., Elanco Animal Health Incorporated, Zoetis Inc., CZ Vaccines, Indian Immunologicals Ltd., Meiji Holdings Co. Ltd., Bioveta A.S., Phibro Animal Health Corporation, Hester Biosciences Limited, High Speed Digieal Processor Architecture Pvt. Ltd., Dechra Pharmaceuticals PLC, Norbrook Inc., Biogenesis Bago SA, Vaxxinova India Private Limited, Bimeda Animal Health Ltd., Lohmann Animal Health GmbH, Biovac Ltd., Zenex Animal Health India Pvt. Ltd., Instituto Rosenbusch S A.

Asia-Pacific was the largest region in the dog vaccines market in 2024. The regions covered in the dog vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dog vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Dog vaccines constitute a series of administered injections, commencing during the puppy stage and extending into adulthood. These vaccines aim to introduce small amounts of a virus particle to trigger an immune response in the dog's body. This proactive measure enables the dog to mount an immune defense in the event of exposure to bacteria or viruses, thereby preventing illness.

Key categories of dog vaccines encompass attenuated live vaccines, conjugate vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, DNA vaccines, and recombinant vaccines. Attenuated live vaccines involve creating a vaccine by reducing the virulence of a pathogen while maintaining its viability. Administration methods include subcutaneous, intramuscular, and intranasal routes, catering to dogs below 6 months and those above 6 months.

The dog vaccines market research report is one of a series of new reports that provides dog vaccines market statistics, including dog vaccines industry global market size, regional shares, competitors with an dog vaccines market share, detailed dog vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the dog vaccines industry. This dog vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dog vaccines market consists of sales of vaccines for dogs including core dog vaccines, and non-core dog vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.